ICON’s Acquisition of Symphony Clinical Research
October 23 2019 - 4:20PM
Business Wire
Acquisition enhances ICON’s ability to offer
customers hybrid trial solutions and site support services
ICON plc, (NASDAQ: ICLR) a global provider of drug
and device development and commercialisation services to
pharmaceutical, biotechnology, medical device industries, today
announced that it has acquired Symphony Clinical Research, a
leading provider of at-home patient and site support services.
The acquisition, concluded in late September, further enhances
ICON’s patient, site and data strategy and complements ICON’s
existing PMG Research and MeDiNova Research site networks in the US
and EMEA. Symphony’s services reduce the travel burden for patients
which broadens ICON’s recruitable population, providing patients
access to clinical research studies that they may not have
otherwise been able to participate in.
Headquartered in Vernon Hills, Illinois, U.S. and Gdansk,
Poland, Symphony Clinical Research has been operating since 2003
and has serviced global trials in over 50 countries for biopharma
companies across many major therapeutic areas, including
cardiovascular, immunology, oncology and respiratory.
Nicki Norris, Chief Executive Officer, Symphony Clinical
Research, said: “As the pioneer in alternate-site services,
Symphony integrates clinical trial expertise with project
management; in-home care and nursing to bring the site visit to the
patient wherever they live. ICON provides Symphony with a great
opportunity to extend our services globally and to use our
knowledge, infrastructures and network to support ICON to enhance
patient recruitment, engagement and retention”.
Dr. Steve Cutler, Chief Executive Officer, ICON plc, said: “ICON
has a focused patient, site and data strategy which is helping us
to improve site identification, study placement, patient
recruitment and retention. A core objective of our patient centered
approach is to increase predictability in patient recruitment and
improve patient engagement. Symphony Clinical Research further
enhances this approach by providing us with the capability to offer
patients at-home trial services making clinical trials more
accessible for patients and improving enrollment. Symphony’s
clinical trial experience and their strong therapeutic expertise
will also enable us to broaden our hybrid trial solutions to
customers and support services to sites.”
About Symphony Clinical Research
Symphony Clinical Research is the leading global provider of
specialized in-home and alternate-site clinical services. Since
2003, Symphony has been making it convenient to participate in
clinical research by bringing study visits to patients, from
neonates to geriatrics, in all phases and therapeutic areas of
clinical trials.
Symphony has spearheaded the patient-centric in-home study
services movement and has continually been at the forefront of
innovation in clinical research including decentralized, hybrid,
direct-to-patient and virtual trials. We continually strive to
perfect the service model through developing more efficient and
reliable ways to deliver high-quality results.
Symphony’s services have significantly accelerated the pace of
clinical trials by dramatically improving patient recruitment,
retention, compliance and site productivity as well as increasing
patient and investigator satisfaction.
Further information is available at
www.symphonyclinicalresearch.com
About ICON plc
ICON plc is a global provider of drug development solutions and
services to the pharmaceutical, biotechnology and medical device
industries. The company specialises in the strategic development,
management and analysis of programs that support clinical
development - from compound selection to Phase I-IV clinical
studies. With headquarters in Dublin, Ireland, ICON currently,
operates from 99 locations in 40 countries and has approximately
14,600 employees.
Further information is available at www.iconplc.com/patients
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
ICON/ICLR-G
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191023005728/en/
ICON Media Contact Gareth Arnold Weber Shandwick
Telephone: (+44) 0207 4180398 GArnold@webershandwick.com
ICON (NASDAQ:ICLR)
Historical Stock Chart
From Mar 2024 to Apr 2024
ICON (NASDAQ:ICLR)
Historical Stock Chart
From Apr 2023 to Apr 2024